A Phase 3 interventional study of Early Vasopressin and Norepinephrine and Vasopressin for Rescue in Septic Shock, sponsored by Hospital do Coracao. Recruiting at 8 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Hospital do Coracao · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Shock, Septic with a site in Brazil — 3 open to participants now, 4 under way, 4 of them phase 3. Shock, Septic · Brazil.
Among the 30 studies in Shock, Septic with a site in Brazil, this one has the largest planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2024, is one of 9 in phase 3, and was the 28th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →3 of the 30 studies in Shock, Septic with a site in Brazil are open now. Recruiting first, the newest first:
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva · Sites in Brazil
Ages 18+
Hospital Nossa Senhora da Conceicao · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 10 · Phase 4 4
First in 2004; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,800 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 126 across the 25 interventional studies, 73 across the 5 observational. Of the 21 that completed or were terminated, 2 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 30 have an industry lead sponsor. The 10 most frequent:
Hospital do Coracao is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Hospital do Coracao has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
2 of the studies in Shock, Septic with a site in Brazil that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07264543Phase 3Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia IntensivaEarly Methylene Blue in the Microhemodynamics of Septic Patients | 2026-11-30 |
| NCT06464510Phase 3Hospital do CoracaoNorepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Shock, Septic with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The norepinephrine and vasopressin for rescue versus early vasopressin for vasopressor dependent sepsis (NoVa) is a phase 3, multicenter, open-label, randomized controlled trial comparing an early vasopressin initiation strategy versus norepinephrine plus vasopressin initiation only as a rescue strategy for hemodynamic management of critically ill patients with vasopressor dependent sepsis.
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated body response to infection. Its most severe form, septic shock, occurs when underlying circulatory and cellular metabolic abnormalities are pronounced, indicating greater severity and higher mortality. Vasopressor use is a cornerstone aspect in the treatment of critically ill patients with sepsis-associated hemodynamic dysfunction, with norepinephrine, a catecholamine, being the vasopressor of choice.
Vasopressin is an endogenous peptide hormone with potential advantages over norepinephrine in a catecholamine-sparing strategy for treating sepsis-associated hemodynamic dysfunction.
This is a phase 3, multicenter, open-label, randomized controlled trial. Adult patients with sepsis-associated hemodynamic dysfunction in the ICU may be eligible to participate. We aim to enroll 2,800 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After randomization, vasopressin will be initiated and titrated up to 0.04U/min to maintain the target mean arterial pressure (MAP). Concurrently, norepinephrine will be reduced, with the goal of using the maximum dose of vasopressin and minimizing or eliminating the use of norepinephrine, while still maintaining the target MAP.
Drug: Early Vasopressin
After randomization, norepinephrine will be titrated to maintain the target MAP. Vasopressin will be introduced as a rescue strategy only if the norepinephrine dose exceeds 0.5 μg/kg/min. Once vasopressin is initiated, it can be titrated up to 0.04U/min to help maintain the target MAP if the norepinephrine dose remains above 0.5 μg/kg/min.
Drug: Norepinephrine and Vasopressin for Rescue
Early Vasopressin group: Vasopressin up to 0.04U/min initiated after randomization.
Norepinephrine and Vasopressin for Rescue group: Vasopressin up to 0.04U/min initiated only if norepinephrine dose exceeds 0.5 μg/kg/min.
All-cause mortality or renal replacement therapy
Composite of all-cause mortality or renal replacement therapy within 28 days after randomization.
Time frame: 28 days
All-cause mortality
All-cause mortality within 28 days after randomization
Time frame: 28 days
Renal replacement-therapy
Need of renal replacement therapy within 28 days after randomization.
Time frame: 28 days
Renal replacement-free days
Renal-replacement free days are defined by the number of days a patient is alive and free of renal replacement support between randomization and day 28. Non-survivors will be considered to have zero renal replacement-free days.
Time frame: 28 days
ICU-free days
Number of days a patient is alive and outside the ICU between randomization and day 28. Non-survivors will be considered to have zero ICU-free days.
Time frame: 28 days
Hospital-free days
Number of days a patient is alive and outside the hospital between randomization and day 28. Non-survivors will be considered to have zero hospital-free days.
Time frame: 28 days
Organ support-free days and its components
The definition of organ support involves three components: renal replacement therapy, invasive mechanical ventilation, and vasopressor use. Organ support-free days are defined by the number of days a patient is alive and free of all three organ support therapies between randomization and day 28. Non-survivors will be considered to have zero organ support-free days.
Time frame: 28 days
Cardiac arrhythmias
Occurrence of cardiac arrhythmias between randomization and day 28
Time frame: 28 days
Ischemic events
Occurrence of mesenteric ischemia, ischemic stroke, digital ischemia and acute coronary syndrome between randomization and day 28
Time frame: 28 days
Plan to share: Yes — Submission of a statistical analysis plan for the purposed analyses for the Steering Committee evaluation. Compliance with Brazilian data privacy law.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 1 year after study publication
Access criteria: Submission of a statistical analysis plan for the purposed analyses for the Steering Committee evaluation. Compliance with Brazilian data privacy law.
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Aug 2027, 33 months after the start.
Of 45 non-industry phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's planned 33 months is below that.
Counting every sponsor, half of 46 studies reached it within 42 months; a quarter within 16 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital do Coracao